Periocular epithelioid hemangioma: response to bevacizumab and vascular pathogenesis

Arch Ophthalmol. 2012 Sep;130(9):1209-12. doi: 10.1001/archophthalmol.2012.572.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Angiolymphoid Hyperplasia with Eosinophilia / diagnosis
  • Angiolymphoid Hyperplasia with Eosinophilia / drug therapy*
  • Angiolymphoid Hyperplasia with Eosinophilia / etiology
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Blood Vessels / pathology
  • Debridement
  • Eyelid Diseases / diagnosis
  • Eyelid Diseases / drug therapy*
  • Eyelid Diseases / etiology
  • Female
  • Humans
  • Injections, Intralesional
  • Magnetic Resonance Imaging
  • Orbital Diseases / diagnosis
  • Orbital Diseases / drug therapy*
  • Orbital Diseases / etiology
  • Peripheral Vascular Diseases / diagnosis
  • Peripheral Vascular Diseases / drug therapy
  • Peripheral Vascular Diseases / etiology
  • Retrospective Studies
  • Tomography, X-Ray Computed
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab